Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1Melanoma 1Lymphoma, Non-Hodgkin 1Advanced Cancer 1

Interventions

Nivolumab 2radium Ra 223 dichloride 1poly ICLC 1fludarabine phosphate 1fludarabine 1darolutamide 1cabozantinib 1bempegaldesleukin 1Radium-223 1Radiosurgery 1Pluvicto 1Cyclophosphamide 1Blood Specimen Collection 1Abiraterone Acetate 1177Lu-EB-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Castration-resistant Prostate Cancer × bempegaldesleukin × Clear all
NCT03835533 2024-04-12

PORTER

Parker Institute for Cancer Immunotherapy

Phase 1 Completed
43 enrolled 19 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡